Literature DB >> 1478255

Visualization of extrastriatal dopamine D2 receptors in the human brain.

R M Kessler1, N S Mason, J R Votaw, T De Paulis, J A Clanton, M S Ansari, D E Schmidt, R G Manning, R L Bell.   

Abstract

[123I]Epidepride, a potent and selective dopamine D2 radioligand, was administered to a 27 year old normal male volunteer. Single photon tomography revealed that peak striatal uptake occurred at 4 h after injection with a striatal:cerebellar ratio of 7.8 rising to over 100 at 18 h post injection. Uptake above the levels seen in cerebellum was also noted in the thalamus, pituitary, hypothalamus and temporal lobe, particularly medially. Single photon tomography with [123I]epidepride allows visualization of extrastriatal dopamine D2 receptors in man.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1478255     DOI: 10.1016/0014-2999(92)90825-o

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Effect of scatter correction on the compartmental measurement of striatal and extrastriatal dopamine D2 receptors using [123I]epidepride SPET.

Authors:  Masahiro Fujita; Andrea Varrone; Kyeong Min Kim; Hiroshi Watabe; Sami S Zoghbi; Nicholas Seneca; Dnyanesh Tipre; John P Seibyl; Robert B Innis; Hidehiro Iida
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-17       Impact factor: 9.236

2.  SPECT imaging of dopamine receptors with [123I]epidepride: characterization of uptake in the human brain.

Authors:  J Kornhuber; T Brücke; P Angelberger; S Asenbaum; I Podreka
Journal:  J Neural Transm Gen Sect       Date:  1995

3.  A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.

Authors:  P Tibbo; P H Silverstone; A J McEwan; J Scott; A Joshua; K Golberg
Journal:  J Psychiatry Neurosci       Date:  1997-01       Impact factor: 6.186

4.  18F-fallypride binding potential in patients with schizophrenia compared to healthy controls.

Authors:  Douglas S Lehrer; Bradley T Christian; Cemil Kirbas; Meicheng Chiang; Shawn Sidhu; Holly Short; Binquan Wang; Bingzhi Shi; King-Wai Chu; Brian Merrill; Monte S Buchsbaum
Journal:  Schizophr Res       Date:  2010-07-23       Impact factor: 4.939

5.  Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors.

Authors:  W Pirker; T Brücke; M Riedl; M Clodi; A Luger; S Asenbaum; I Podreka; L Deecke
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 6.  Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Authors:  Jodi J Weinstein; Muhammad O Chohan; Mark Slifstein; Lawrence S Kegeles; Holly Moore; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2016-03-31       Impact factor: 13.382

7.  In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates.

Authors:  Mark Slifstein; Dah-Ren Hwang; Yiyun Huang; Ningning Guo; Yasuhiko Sudo; Raj Narendran; Peter Talbot; Marc Laruelle
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

Review 8.  The Emerging Role of SPECT Functional Neuroimaging in Schizophrenia and Depression.

Authors:  Anil Kalyoncu; Ali Saffet Gonul
Journal:  Front Psychiatry       Date:  2021-12-15       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.